These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16807446)
1. Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Pastorelli D; Cartei G; Zustovich F; Marchese F; Artioli G; Zovato S; Binato S; Ceravolo R; Cingarlini S; Salmaso F; Mattiazzi M; Sanavio C; Farinati F; Zanus G; Cillo U Ann Oncol; 2006 May; 17 Suppl 5():v153-7. PubMed ID: 16807446 [TBL] [Abstract][Full Text] [Related]
2. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. Poh SB; Bai LY; Chen PM Am J Clin Oncol; 2005 Dec; 28(6):540-6. PubMed ID: 16317261 [TBL] [Abstract][Full Text] [Related]
3. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436 [TBL] [Abstract][Full Text] [Related]
4. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Lombardi G; Zustovich F; Farinati F; Cillo U; Vitale A; Zanus G; Donach M; Farina M; Zovato S; Pastorelli D Cancer; 2011 Jan; 117(1):125-33. PubMed ID: 21058409 [TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Yang TS; Wang CH; Hsieh RK; Chen JS; Fung MC Ann Oncol; 2002 Nov; 13(11):1771-8. PubMed ID: 12419750 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545 [TBL] [Abstract][Full Text] [Related]
7. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814 [TBL] [Abstract][Full Text] [Related]
13. A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Davis EJ; Griffith KA; Kim EJ; Ruch JM; McDonnell KJ; Zalupski MM Am J Clin Oncol; 2018 Feb; 41(2):128-132. PubMed ID: 26535993 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844 [TBL] [Abstract][Full Text] [Related]
15. Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer. Shibata Y Gan To Kagaku Ryoho; 2014 Dec; 41(13):2599-602. PubMed ID: 25596055 [TBL] [Abstract][Full Text] [Related]
16. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Sasahira N; Hirano K; Tsujino T; Tada M; Omata M; Koike K Invest New Drugs; 2011 Dec; 29(6):1488-93. PubMed ID: 20607585 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731 [TBL] [Abstract][Full Text] [Related]
19. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Thongprasert S; Napapan S; Charoentum C; Moonprakan S Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]